Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Ultra Short Income ETF (JPST) vs Medtronic PLC (MDT) Price & Performance

JPMorgan Ultra Short Income ETFTrade
Medtronic PLCTrade

Price performance (Past 24H)

Key statistics

JPMorgan Ultra Short Income ETF vs Medtronic PLC — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.46, while Medtronic PLC trades at $90.48 (market cap $114.45B). The key difference: Medtronic PLC pays a 3.22% dividend while JPMorgan Ultra Short Income ETF pays none, and Medtronic PLC is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.

JPSTMDT
Sector
Leveraged / InverseHealth
52-Week High
$50.78$105.35
52-Week Low
$50.40$73.75
Market Cap
$114.45B
Enterprise Value
$133.19B
Dividend Yield
3.22%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Ultra Short Income ETF

JPST (JPMorgan Ultra-Short Income ETF) trades at $50.44, showing minimal daily movement with a 0.08% gain. The technical picture remains bearish with moving averages signaling caution, though the RSI suggests potential oversold conditions. Recent institutional activity shows growing interest, with Financial Management Professionals increasing their stake by 4.7% in Q2 2026. The fund maintains consistent dividend distributions of $0.17 per share, providing stable income for risk-averse investors seeking short-term bond exposure.

As an ultra-short income ETF, JPST offers conservative investors a cash-alternative with slightly higher yields than T-bills. The fund's stability and consistent dividends make it attractive for parking cash between investments or during uncertain rate environments. However, rising interest rates and inflation pressures pose headwinds for short-term bond performance. The ETF's bearish technical signals warrant monitoring, though its defensive positioning provides downside protection in volatile markets.

Medtronic PLC

Medtronic (MDT) trades at $87.16, up 1.44% today, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $1.55, exceeding expectations, and maintains solid fundamentals with a 13.2% net income margin and $33.54B in revenue for 2025. Recent news highlights growth in cardiac ablation and the Hugo robotic platform, with management guiding for 11.75% organic revenue growth in Q1 2027.

The outlook is positive, supported by analyst consensus of a $98.75 price target and 60% buy ratings. Key opportunities include dividend stability and innovation in medical technology, while risks involve rising debt levels and competitive pressures. The stock's current valuation at a P/E of 23.37 offers moderate upside if execution continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About JPMorgan Ultra Short Income ETF

JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.

Read more on JPST

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT